| P50 | author | Eric O Freed | Q67208349 |
| | Christos J Petropoulos | Q84542015 |
| | Rodrigo Brindeiro | Q91113863 |
| P2093 | author name string | Wei Huang | |
| | Alicia Newton | |
| | Abdul A Waheed | |
| | Angelica N Martins | |
| | Sherimay D Ablan | |
| P2860 | cites work | Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding | Q24291784 |
| | Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function | Q24530772 |
| | Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities | Q24550608 |
| | Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release | Q24563651 |
| | Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides | Q24627225 |
| | Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag) | Q24633537 |
| | Virus budding and the ESCRT pathway | Q26828590 |
| | Current perspectives on HIV-1 antiretroviral drug resistance | Q26852626 |
| | The choreography of HIV-1 proteolytic processing and virion assembly | Q27009643 |
| | HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress | Q28207991 |
| | Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 |
| | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites | Q28379086 |
| | A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism | Q28469113 |
| | Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss | Q28474984 |
| | Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity | Q28710568 |
| | Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 |
| | Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease | Q30850215 |
| | The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation | Q33727091 |
| | Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. | Q33783498 |
| | Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity | Q33791156 |
| | Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity | Q33837707 |
| | Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein | Q33846417 |
| | A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 |
| | Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins | Q34098983 |
| | The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner | Q34104639 |
| | p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease | Q34288376 |
| | Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription | Q34614167 |
| | Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness | Q34651403 |
| | Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review | Q34969496 |
| | Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy | Q34989641 |
| | Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. | Q35237575 |
| | Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. | Q35548279 |
| | Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1 | Q36098898 |
| | Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. | Q36632356 |
| | Expression and processing of human immunodeficiency virus type 1 gag and pol genes by cells infected with a recombinant vaccinia virus | Q36782067 |
| | The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors | Q36881276 |
| | Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity | Q36944098 |
| | Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings | Q37003942 |
| | New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors | Q37262113 |
| | Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations | Q37333801 |
| | HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. | Q37447762 |
| | The cell biology of HIV-1 virion genesis | Q37520101 |
| | Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors | Q37583389 |
| | Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease | Q37596952 |
| | HIV-1 assembly, budding, and maturation | Q38023864 |
| | Retroviral proteases and their roles in virion maturation | Q38393674 |
| | HIV-1 assembly, release and maturation. | Q38539565 |
| | Role of Gag in HIV Resistance to Protease Inhibitors | Q38615581 |
| | Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. | Q39550343 |
| | Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 |
| | Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. | Q39579408 |
| | Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | Q39580564 |
| | Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir | Q39601382 |
| | Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro | Q39684211 |
| | Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients | Q39735514 |
| | Methods for the study of HIV-1 assembly. | Q39914278 |
| | The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. | Q40042979 |
| | Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail | Q40579232 |
| | Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors | Q40763780 |
| | Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance | Q41913817 |
| | Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease. | Q42206980 |
| | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | Q42546287 |
| | Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals | Q43240921 |
| | Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. | Q43690629 |
| | Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus | Q43691016 |
| | Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. | Q44103766 |
| | Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy | Q45728754 |
| | Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection | Q45760752 |
| | Versatile PCR-mediated insertion or deletion mutagenesis | Q47901424 |
| | Accumulation of P(T/S)AP Late Domain Duplications in HIV Type 1 Subtypes B, C, and F Derived from Individuals Failing ARV Therapy and ARV Drug-Naive Patients | Q48061694 |
| | The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. | Q51873753 |
| | Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. | Q51936440 |
| | Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. | Q53570987 |
| | Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease | Q69564852 |
| | HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays | Q74213231 |
| | Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors | Q74220146 |
| | Variability in the P6gag domains of HIV-1 involved in viral budding | Q82519683 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| P304 | page(s) | 768-779 | |
| P577 | publication date | 2015-10-28 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain | |
| P478 | volume | 90 | |